

Docket No. 238027US0CONT/phh



*Free*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Junji HAMURO, et al.

SERIAL NO: 10/603,800

GAU: 1636

FILED: June 26, 2003

EXAMINER:

FOR: TRANSPLANT REJECTION SUPPRESSOR

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references cited in the attached European Search Report listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon

Vincent K. Shier, Ph.D.  
Registration No. 50,552

Customer Number

22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

Roland E. Martin  
Registration No. 48,082

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 238027US0CONT		SERIAL NO. 10/603,800	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Junji HAMURO, et al.			
FILING DATE June 26, 2003				GROUP 1636			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AO	2,268,462	10/09/2000	CANADA			
	AP						
	AQ						
	AR						
	AS						
	AT						
	AU						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AV	A. SOOTS, et al., Transplantation, vol. 25, no. 5, XP-000934381, pages 259-264, "PROLONGATION OF RAT CARDIAC ALLOGRAFT SURVIVAL BY DONOR PRETREATMENT", 1978					
	AW	M. SUTHANTHIRAN, et al., Proc. Natl. Acad. Sci. USA, vol. 87, no. 9, XP-002283266, pages 3343-3347, "GLUTATHIONE REGULATES ACTIVATION-DEPENDENT DNA SYNTHESIS IN HIGHLY PURIFIED NORMAL HUMAN T LYMPHOCYTES STIMULATED VIA THE CD2 AND CD3 ANTIGENS", May 1990					
	AX	C. P. ANDERSON, et al., European Journal of Cancer, vol. 33, no. 12, XP-004284637, pages 2016-2019, "BUTHIONINE SULPHOXIMINE ALONE AND IN COMBINATION WITH MELPHALAN (L-PAM) IS HIGHLY CYTOTOXIC FOR HUMAN NEUROBLASTOMA CELL LINES", October 1997					
	AY	Y. TOMITA, et al., Journal of Immunology, vol. 165, no. 1, XP-002283267, pages 34-41, "INDUCTION OF PERMANENT MIXED CHIMERISM AND SKIN ALLOGRAFT TOLERANCE ACROSS FULLY MHC-MISMATCHED BARRIERS BY THE ADDITIONAL MYELOSUPPRESSIVE TREATMENTS IN MICE PRIMED WITH ALLOGENEIC SPLEEN CELLS FOLLOWED BY CYCLOPHOSPHAMIDE", July 1, 2000					
	AZ					<input type="checkbox"/> Additional References sheet(s) attached	
Examiner					Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							